Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 4.8% – Should You Sell?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares dropped 4.8% during mid-day trading on Friday . The company traded as low as $5.24 and last traded at $5.2350. Approximately 193,861 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 3,402,044 shares. The stock had previously closed at $5.50.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TSHA. Wall Street Zen raised shares of Taysha Gene Therapies from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Chardan Capital restated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. Citizens Jmp lifted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday. Finally, The Goldman Sachs Group set a $11.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $10.42.

Taysha Gene Therapies Stock Down 5.4%

The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The company has a 50 day moving average of $4.90 and a 200-day moving average of $3.76. The company has a market capitalization of $1.43 billion, a P/E ratio of -15.77 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. As a group, equities analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 260,047 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $4.51, for a total value of $1,172,811.97. Following the completion of the transaction, the insider owned 1,006,439 shares in the company, valued at $4,539,039.89. The trade was a 20.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 3.78% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of hedge funds have recently bought and sold shares of the business. Marex Group plc purchased a new position in shares of Taysha Gene Therapies in the second quarter worth $29,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies in the second quarter worth about $31,000. ST Germain D J Co. Inc. grew its stake in shares of Taysha Gene Therapies by 81.8% during the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after buying an additional 4,333 shares during the last quarter. May Hill Capital LLC purchased a new stake in shares of Taysha Gene Therapies in the second quarter worth approximately $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth approximately $40,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.